Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer.

Leiszter K, Sipos F, Galamb O, Krenács T, Veres G, Wichmann B, Fűri I, Kalmár A, Patai ÁV, Tóth K, Valcz G, Tulassay Z, Molnár B.

PLoS One. 2015 Feb 27;10(2):e0118332. doi: 10.1371/journal.pone.0118332. eCollection 2015.

2.

Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity.

Ayiomamitis GD, Notas G, Zaravinos A, Drygiannakis I, Georgiadou M, Sfakianaki O, Mastrodimou N, Thermos K, Kouroumalis E.

Oncoscience. 2014 Jun 30;1(6):457-67. eCollection 2014.

PMID:
25594044
Free PMC Article
3.

Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M.

Front Endocrinol (Lausanne). 2014 Feb 7;5:7. doi: 10.3389/fendo.2014.00007. eCollection 2014. Review.

4.

Somatostatin receptor expression in thyroid disease.

Atkinson H, England JA, Rafferty A, Jesudason V, Bedford K, Karsai L, Atkin SL.

Int J Exp Pathol. 2013 Jun;94(3):226-9. doi: 10.1111/iep.12024.

5.

A review of the use of somatostatin analogs in oncology.

Keskin O, Yalcin S.

Onco Targets Ther. 2013 Apr 26;6:471-83. doi: 10.2147/OTT.S39987. Print 2013.

6.

Positron emission tomography imaging of cancer biology: current status and future prospects.

Chen K, Chen X.

Semin Oncol. 2011 Feb;38(1):70-86. doi: 10.1053/j.seminoncol.2010.11.005. Review.

7.

Applications of molecular imaging.

Galbán CJ, Galbán S, Van Dort ME, Luker GD, Bhojani MS, Rehemtulla A, Ross BD.

Prog Mol Biol Transl Sci. 2010;95:237-98. doi: 10.1016/B978-0-12-385071-3.00009-5. Review.

8.

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Appetecchia M, Baldelli R.

J Exp Clin Cancer Res. 2010 Mar 2;29:19. doi: 10.1186/1756-9966-29-19. Review.

9.

PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.

Van Dort ME, Rehemtulla A, Ross BD.

Curr Comput Aided Drug Des. 2008;4(1):46-53.

10.

Somatostatin and cancer: applying endocrinology to oncology.

Grimberg A.

Cancer Biol Ther. 2004 Aug;3(8):731-3. Epub 2004 Aug 23.

11.

Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.

Wang JH, Xing QT, Yuan MB.

World J Gastroenterol. 2004 Apr 1;10(7):1043-6.

12.

Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase.

Gao S, Yu BP, Li Y, Dong WG, Luo HS.

World J Gastroenterol. 2003 Oct;9(10):2362-5.

13.

Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.

Stirnweiss J, Hartrodt B, Greksch G, Stürzebecher U, Böhmer FD, Neubert K, Liebmann C.

Br J Pharmacol. 2003 Sep;140(1):13-22. Epub 2003 Aug 4.

Items per page

Supplemental Content

Write to the Help Desk